Literature DB >> 14704037

MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.

Takayuki Tsujioka1, Hideho Wada, Shunji Yamamori, Takemi Otsuki, Sinichiro Suemori, Toshinori Kondo, Hidekazu Nakanishi, Yoshimasa Suetsugu, Makoto Mikami, Takashi Sugihara.   

Abstract

We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion. This case suggests that careful monitoring for MLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14704037     DOI： 10.1007/bf02983817

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  25 in total

1.  Therapy-related acute myeloid leukemia with t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)(q22;q21)

Authors:  H Sawada; H Morimoto; A Wake; Y Yamasaki; Y Izumi
Journal:  Int J Hematol       Date:  1999-06       Impact factor: 2.490

Review 2.  The structural era of endocytosis.

Authors:  M Marsh; H T McMahon
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

3.  The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.

Authors:  D Rogaia; F Grignani; R Carbone; D Riganelli; F LoCoco; T Nakamura; C M Croce; P P Di Fiore; P G Pelicci
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

4.  Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.

Authors:  S Mathew; D Head; J E Rubnitz; S C Raimondi
Journal:  Genes Chromosomes Cancer       Date:  2000-06       Impact factor: 5.006

5.  Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.

Authors:  K Takeyama; M Seto; N Uike; N Hamajima; T Ino; C Mikuni; T Kobayashi; A Maruta; Y Muto; N Maseki; H Sakamaki; H Saitoh; M Shimoyama; R Ueda
Journal:  Int J Hematol       Date:  2000-02       Impact factor: 2.490

Review 6.  Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.

Authors:  Hervé Dombret; Pierre Fenaux; Steven L Soignet; Martin S Tallman
Journal:  Semin Hematol       Date:  2002-04       Impact factor: 3.851

Review 7.  Chromosome abnormalities in leukaemia: the 11q23 paradigm.

Authors:  B D Young; V Saha
Journal:  Cancer Surv       Date:  1996

Review 8.  Epidermal growth factor pathway substrate 15, Eps15.

Authors:  A E Salcini; H Chen; G Iannolo; P De Camilli; P P Di Fiore
Journal:  Int J Biochem Cell Biol       Date:  1999-08       Impact factor: 5.085

9.  Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.

Authors:  N Watanabe; H Kobayashi; O Ichiji; M A Yoshida; A Kikuta; Y Komada; I Sekine; Y Ishida; Y Horiukoshi; Y Tsunematsu; M Yano; H Nakadate; Y Kaneko
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

Review 10.  Retinoic acid resistance in acute promyelocytic leukemia.

Authors:  R E Gallagher
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.